Aptargroup Inc
24/7 Wall St. View
ATR at a Glance
- Market cap
- $9.1B
- P/E ratio
- 34.6
- Dividend yield
- 1.34%
- Revenue (TTM)
- $4.0B
- Profit margin
- 6.7%
- EPS (TTM)
- $4.14
- 52-week range
- $110 – $148
- 24/7 target
- $179.14
- Street target
- $163.88
- Next report
- Feb 3, 2027
Headquartered in Crystal Lake, IL Fiscal year ends December NYSE: ATR aptar.com
About AptarGroup
AptarGroup (Aptar) designs and manufactures drug delivery, dosing and protection technologies and consumer product dispensing systems. It sells to pharmaceutical, beauty, personal care, food and beverage companies. The company reports three segments:
- **Pharma:** Nasal, pulmonary, ophthalmic, dermal and injectable drug delivery components and systems. These serve central nervous system therapies, consumer healthcare, emergency medicine, biologics, vaccines and GLP-1 therapies. The segment also earns royalties.
- **Beauty:** Dispensing systems for prestige fragrance, color cosmetics, skin and hair care.
- **Closures:** Dispensing closures for beverages (including bottled water and concentrates), food and condiments.
Aptar pairs proprietary design, engineering and science with customer partnerships across the drug development cycle. It employs about 14,000 people in 20 countries. In the third quarter of 2026 it deconsolidated its Russian subsidiary after a government-imposed external administration, and Gael Touya began his tenure as President and CEO. Updated
Frequently Asked Questions
What does AptarGroup do?
AptarGroup (Aptar) designs and manufactures drug delivery, dosing and protection technologies and consumer product dispensing systems. It sells to pharmaceutical, beauty, personal care, food and beverage companies.
What is the ATR stock price target?
24/7 Wall St.'s 12-month price target for ATR is $179.14, rated Buy. The Wall Street consensus target is $163.88. ATR price prediction →